Former investment banker appointed CFO of AKL

AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, has announced the appointment of Michael Martin as its Chief Financial Officer. With more than 40 years’ global corporate finance experience advising companies in Mergers & Acquisitions, Initial Public Offerings and private equity, Mr Martin brings a wealth of deal experience to […]

Read More

AKLRD and Nordic Bioscience announce collaboration

AKL Research and Development (AKLRD) and Nordic Bioscience Clinical Development, have announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of Osteoarthritis (OA). The collaboration was announced at the Osteoarthritis Research Society International (OARSI) World Congress 2019 in Toronto, Canada.  The partnership will assess the […]

Read More

An important milestone in the development of APPA

The Phase I clinical trial at Liverpool is designed to test the safety of APPA.  The first stage is now complete, and the clinical trial dose escalation committee has approved the transition from a single dose in healthy volunteers to multiple ascending 2 week dosing in osteoarthritis patients. In this part of a clinical trial, […]

Read More

Dr Annalisa Jenkins and Lord Michael Grade as Advisors

AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, announces the appointment of Dr Annalisa Jenkins and Lord Michael Grade as advisors. Dr Jenkins is former Head of Global Research & Development and Executive Vice President Global Development & Medical at Merck Serono. Lord Grade is former Chairman of the BBC. […]

Read More

More weight loss tied to less knee pain for obese people

A recent article from Reuters Health has highlighted research by the American College of Rheumatology whose researchers have determined that obese people with knee osteoarthritis, a painful joint disease, may find greater symptom relief when they lose larger amounts of weight than when they shed fewer pounds, a recent study suggests. The researchers examined data […]

Read More

Phase I Clinical Trial at the University of Liverpool

The Phase I Clinical Trial to test AKL’s lead anti-inflammatory clinical candidate, APPA, as a potential new treatment for osteoarthritis is underway at the University of Liverpool Clinical Trials Unit. The trial has been approved for NIHR support. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million […]

Read More